Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the company said Monday. GlycoMimetics (NASDAQ: GLYC) will receive $9 million in cash upfront and around $180 million in milestone…
from https://www.bizjournals.com/baltimore/news/2020/01/07/md-biotech-strikes-deal-worth-millions-to-break.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/190122062752
No comments:
Post a Comment